Clara Tourino PhD
Translational Neuroscience & In Vivo Strategy Consultant
With over 25 years of hands-on experience in preclinical in vivo research, Clara founded NeuroVivo LLC to help institutions navigate the technical, operational, and regulatory complexities of in vivo studies. Her career spans academia, biotech, and translational neuroscience, where she has led teams, built facilities, and solved high-stakes challenges across the US and Europe.
Clara began her scientific journey in Barcelona, earning a PhD in Neuropharmacology from Pompeu Fabra University. Her early research on the genetic basis of substance abuse and psychiatric disorders evolved into postdoctoral work at Stanford, where she pioneered optogenetic techniques and mentored emerging scientists.
She later transitioned into biotech leadership, directing in vivo biology programs at Prothena Biosciences and Switch Therapeutics, where she spearheaded PK/PD and efficacy strategy in preclinical models, managed cross-species CRO partnerships, and oversaw animal facilities and regulatory committees with precision and integrity.
Now, through NeuroVivo LLC, Clara offers strategic consulting to sponsors and institutions seeking to build, validate, or optimize their in vivo capabilities.
NeuroVivo’s services include feasibility assessments of AI-generated study designs, CRO–sponsor liaison support, and operational data auditing for pharma teams evaluating acquisition candidates. Whether troubleshooting experimental variability, guiding cross-functional teams through complex preclinical programs, or advising on regulatory documentation, Clara brings a rare blend of technical depth, regulatory fluency, and collaborative spirit—grounding visionary ideas in real-world execution.
Clara is known for translating complex data into actionable strategy. Her mission is simple: to elevate in vivo research through precision, integrity, and practical expertise.
Hsing-Chen Tsai, PhD
Cell & Gene Therapy Development Consultant
Dr. Hsing-Chen Tsai brings over 20 years of experience in neuroscience, gene therapy, and translational pharmacology to NeuroVivo’s consulting team. Her career spans biotech leadership roles at Kelonia Therapeutics, bluebird bio, Alector Therapeutics, and Pfizer, where she directed IND-enabling programs, managed multi-species CRO partnerships, and led cross-functional teams through complex preclinical development.
At Kelonia, she oversaw the in vivo pharmacology strategy for KLN-1010, an in vivo CAR-T therapy now in clinical trials, and authored key IND study reports.
At bluebird bio, she led 2 ex vivo gene therapy pipeline programs and spearheaded the company’s first in vivo gene therapy pipeline, integrating ocular and CNS models with strategic advisory input and external CRO execution.
Hsing-Chen’s expertise includes viral vector platforms (AAV, LVV), optogenetics, biomarker strategy, and regulatory documentation. She has designed and executed dozens of preclinical studies across rodent, canine, and nonhuman primate models, and has trained scientific teams in both technique and strategy. At NeuroVivo, she contributes to feasibility assessments, data auditing, and sponsor–CRO alignment, helping clients translate complex datasets into actionable decisions with precision and clarity.
Gloria Mas Martin, PhD
Translational Oncology Consultant
Dr. Gloria Mas Martin is a translational research leader with over 15 years of experience integrating in vivo models with multi-omic biomarker discovery to inform therapeutic strategy. At the University of Miami’s Sylvester Comprehensive Cancer Center, she built and led a robust PDX portfolio spanning glioblastoma, hematologic malignancies, and humanized models—designing efficacy, PK/PD, and survival studies that directly supported clinical decision-making. Her expertise in orthotopic engraftment, longitudinal imaging, and immune-tumor modeling is complemented by deep fluency in spatial-omics, digital pathology, and regulatory operations.
Gloria has held leadership roles across academic and biotech settings, including Galvanize Therapeutics and Invitae, where she managed complex clinical datasets and multi-stakeholder programs. At NeuroVivo, she contributes to study design validation, biomarker strategy, and data interpretation for sponsors seeking to bridge preclinical findings with clinical relevance. Her ability to translate complex datasets into actionable insights makes her a vital partner for teams navigating oncology development and acquisition decisions.
Mission and values
Mission
At NeuroVivo LLC, our mission is to elevate in vivo research by delivering tailored, expert-driven solutions that empower institutions to achieve scientific excellence. We partner with clients to validate, refine, and troubleshoot their in vivo strategies—ensuring every study is grounded in operational feasibility, regulatory clarity, and scientific rigor.
Core Values
Scientific Rigor
We uphold the highest standards of experimental design, technique execution, and data integrity—because meaningful science begins with uncompromising quality.
Tailored Solutions
Every client, facility, and study is unique. We listen deeply, adapt intelligently, and deliver customized strategies that align with your goals, resources, and timelines.
Strategic Clarity
We help clients cut through complexity—connecting data, design, and execution to support confident decision-making at every stage of development.
Collaborative Partnership
We work alongside your team—not above it—to foster trust, transparency, and shared success. Our goal is to strengthen your capabilities, not replace them.
Regulatory Integrity
From IACUC protocols to IND-enabling documentation, we help you navigate compliance with confidence—translating complex requirements into clear, actionable steps.We uphold the highest standards of experimental design, technique execution, and data integrity—because meaningful science begins with uncompromising quality.
Operational Impact
We focus on solutions that work in the real world. Whether troubleshooting variability, managing CROs, or validating AI-generated designs, our guidance is practical, scalable, and results-oriented.